VisEn launches fluorescence molecular imaging agent
VisEn Medical’s IntegriSense fluorescence in vivo imaging agent product line is now commercially available.
The agent is the first product developed out of the Merck-VisEn Biomarker Imaging research collaboration announced in 2007, and will enable researchers to image and assess the role of integrin alpha v beta 3 in disease progression and therapeutic response in vivo, according to the Bedford, Mass.-based company.
IntegriSense is an optimized in vivo fluorescence imaging agent targeting integrin alpha v beta 3, a biomarker associated with disease-related vascularity and angiogenesis. VisEn said that the agent is designed to measure and monitor aspects of disease progression and therapeutic response in disease states including oncology, cardiovascular disease and bone disease.
The agent is the first product developed out of the Merck-VisEn Biomarker Imaging research collaboration announced in 2007, and will enable researchers to image and assess the role of integrin alpha v beta 3 in disease progression and therapeutic response in vivo, according to the Bedford, Mass.-based company.
IntegriSense is an optimized in vivo fluorescence imaging agent targeting integrin alpha v beta 3, a biomarker associated with disease-related vascularity and angiogenesis. VisEn said that the agent is designed to measure and monitor aspects of disease progression and therapeutic response in disease states including oncology, cardiovascular disease and bone disease.